title: Evolution of care for patients with relapsed glioblastoma.
abstract: Glioblastoma is the most common and aggressive form of brain tumor in adults and has a poor prognosis and a high recurrence rate despite optimal care. The management of patients with relapsed glioblastoma is challenging, with no widely agreed standard of care. Different chemotherapy and radiotherapy combination treatment strategies provide only modest benefits. Recently, several novel agents, including bevacizumab and XL-184, have demonstrated promising results in Phase II trials with their further evaluation ongoing in Phase III randomized trials. Interpreting the data from such trials is a key challenge in glioblastoma, highlighting the need for relevant and standardized patient assessment techniques. Data from ongoing and planned trials should help to define optimal treatment strategies for this disease.
authors: Medical Oncology Service, Institut Català d'Oncologia, Germans Trias i Pujol, Carretera Canyet sn, 08916 Badalona, Barcelona, Spain. cbalana@iconcologia.net
authors: Carmen
authors: C
authors: Balañá
authors: Salvador
authors: S
authors: Villá
authors: Pilar
authors: P
authors: Teixidor
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005909:Glioblastoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D006801:Humans; D011379:Prognosis; D012008:Recurrence
chemical_list: D000970:Antineoplastic Agents